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ABSTRACT : 
 
Objective. A hallmark of rheumatoid arthritis (RA) is the chronic pain that 
accompanies the inflammation and joint deformation. Patients with RA rate pain 
relief with highest priority, however, few studies have addressed the efficacy and 
safety of therapies directed specifically towards pain pathways. The conotoxin 
MVIIA (Prialt/Ziconotide) is used in humans to alleviate persistent pain syndromes 
because it specifically blocks the CaV2.2 voltage-gated calcium channel, which 
mediates the release of neurotransmitters and proinflammatory mediators from 
peripheral nociceptor nerve terminals. The purpose of this study was to 
investigate whether block of CaV2.2 can suppress arthritic pain, and to examine 
the progression of induced arthritis during persistent CaV2.2 blockade. 
Methods. Transgenic mice (Tg-MVIIA) expressing a membrane-tethered form 
of the ω-conotoxin MVIIA, under the control of a nociceptor-specific gene, were 
employed. These mice were subjected to unilateral induction of joint inflammation 
using the Antigen- and Collagen-Induced Arthritis (ACIA) model.  
Results. We observed that CaV2.2-blockade mediated by t-MVIIA effectively 
suppressed arthritis-induced pain; however, in contrast to their wild-type 
littermates, which ultimately regained use of their injured joint as inflammation 
subsides, Tg-MVIIA mice showed continued inflammation with an up-regulation of 
the osteoclast activator RANKL and concomitant joint and bone destruction. 
Conclusion. Altogether, our results indicate that alleviation of peripheral 
pain by blockade of CaV2.2- mediated calcium influx and signaling in nociceptor 
sensory neurons, impairs recovery from induced arthritis and point to the 
potentially devastating effects of using CaV2.2 channel blockers as analgesics 
during inflammation.  
 
Abbreviations AALAC, Association for Assessment and Accreditation of Laboratory Animal 
Care; ACIA, Antigen- and Collagen-Induced Arthritis; ACPA, anti–citrullinated peptide antibodies; 
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AIDS, acquired immunodeficiency syndrome; BAC, bacterial artificial chromosome; BSA, bovine 
serum albumin; CaV, N-type voltage-gated calcium channel; CFA, Freund's complete adjuvant; 
CGRP, calcitonin-gene related peptide; DMARD, disease modifying anti-rheumatic drugs; DRG, 
dorsal root ganglia; ELISA, enzyme-linked immunosorbent assay; GPI, 
glycosylphosphatidylinositol; HE, hematoxylin and eosin; ICFA, Freund's incomplete adjuvant; 
IACUC, Institutional Animal Care and Use Committee; IL-17, interleukin-17; mBSA, methylated 
bovine serum albumin; MCP-1, monocyte chemotactic protein-1; MCV, mutated citrullinated 
vimentin; MFI, mean fluorescence intensity; MVIIA, a ω-conotoxin blocking N-type voltage-gated 
calcium channels; NGF, nerve-growth factor; NSAIDs, non-steroidal anti-inflammatory drugs; PE, 
phycoerythrin; PMA, phorbol 12-myristate 13-acetate; PTx, pertussis toxin; RA, rheumatoid 
arthritis; RANKL, receptor activator of nuclear factor kappa-B ligand; t-MVIIA, tethered MVIIA; 
TMB, tetramethylbenzidine; Tg-MVIIA, transgenice MVIIA mice; TNFα, tumor necrosis factor 
alpha; wt, wild type. 
 
 
INTRODUCTION 
 
Rheumatoid arthritis (RA) is a chronic inflammatory autoimmune disorder that affects 1-2% of the 
worldwide population with a prevalence that increases with age, especially in women. It is 
characterized by a persistent erosive synovitis that can lead to severe damage, disability and 
loss of function of the affected joints, and to chronic pain (1). Current treatments aim at reducing 
inflammation to slow down the irreversible joint damage and to relieve inflammatory pain. 
Recently it has been hypothesized that sensitization of the nociceptive system may contribute to 
the intensity and chronicity of the pain accompanying rheumatic diseases (2-4).   
The transmission of pain relies on voltage-dependent Ca2+ channels, in particular on CaV2.2, 
which is critically involved in nociceptor sensory transmitter release (5) and is considered a target 
to control osteoarthritis pain (6). CaV2.2 can be specifically blocked by the ω-conotoxin MVIIA. 
The synthetic form of the MVIIA conotoxin, commercialized as ziconotide or Prialt®, was 
approved in 2004 for the treatment of severe chronic pain associated with cancer, AIDS, 
inflammatory pain and neuropathies and cases of intractable morphine-insensitive pain. 
Importantly, ziconotide acts synergistically with opioid analgesics without inducing tolerance or 
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addiction (7). However, its use requires intrathecal microinfusion pumps to minimize side effects 
on central nervous system channels, which can cause psychosis over a certain threshold. 
Recent efforts to chemically re-engineer conotoxins have lead to more stable cyclic forms that 
can be administered orally rather than intrathecally (8). If given orally, conotoxins may prove 
useful in managing pain in chronic inflammatory disorders like arthritis. However, the effect of 
CaV2.2-blockade on ongoing tissue inflammation in chronic inflammation or autoimmunity has so 
far not been addressed. 
In the present study we investigated the contribution of CaV2.2 to the development of arthritis and 
the possible side-effects of targeting CaV2.2 in inflammatory pain management. To this end we 
employed pain-insensitive transgenic mice (Tg-MVIIA) that expressω-conotoxin MVIIA under 
control of the regulatory regions of the nociceptor-specific Scn10a gene and thus selectively 
block CaV2.2 channels in nociceptors (9). In the context of our study it was essential to use a 
preclinical arthritis model that recapitulates the erosive inflammatory joint disease progression, 
and its autoimmune character, including the development of anti–citrullinated peptide antibodies 
(ACPA) that occur in RA patients (10). ACPA are particularly interesting as they might be directly 
involved in the differentiation of osteoclast precursors into mature bone resorbing cells (11). 
Therefore, we chose the Antigen- and Collagen-induced arthritis (ACIA) model that unlike 
commonly used mouse models, effectively mimics the long lasting aspect of erosive synovitis 
along with autoimmune signs like the presence ACPA (12).  
The synovial joint inflammation is to a large extent driven by TNFα (13), which also regulates the 
expression of RANKL (Receptor Activator of Nuclear factor Kappa-B Ligand; also known as 
OPGL, ODF and TRANCE), the main mediator of osteoclastogenesis and inflammatory bone 
resorption (14). In RA, RANKL is expressed by synovial fibroblasts and activated synovial T cells. 
It triggers osteoclastogenesis and bone loss (15, 16), and promotes arthritis-induced joint 
destruction in the inflamed synovium (17). Therefore we investigated RANKL expression in the 
inflamed joints of arthritic wt mice and pain-insensitive Tg-MVIIA mice. 
We showed that CaV2.2 blockade effectively suppresses arthritis-induced pain but prolongs the 
ongoing inflammation leading to drastic joint deformation via the up-regulation of the osteoclast 
activator RANKL. 
 
MATERIALS AND METHODS: 
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Mice 
For the generation of Tg-MVIIA mice, a BAC clone (RP23-214H2) encompassing the Scn10a 
gene was modified to include the t-MVIIA expression cassette (9). Mice were backcrossed to the 
C57BL/6 strain (from Charles River) for 10 generations. All procedures are registered and 
approved by the appropriate German federal authorities and by the Institutional Animal Care and 
Use Committee (IACUC) of the Rockefeller University (protocol 11444).  
Antigen- and Collagen-induced Arthritis (ACIA) model 
Mice were immunized s.c. with 100 µg mBSA (Sigma-Aldrich, Schnelldorf, Germany) in PBS 
emulsified with complete Freund's adjuvant (Sigma-Aldrich). One week later, mice were 
immunized s.c. with 50 µg mBSA and 100 µg bovine collagen type II (mdbioproducts, Zurich, 
Switzerland) emulsified with Freund’s incomplete adjuvant (Sigma-Aldrich). In parallel to each 
immunization step, 200 ng of Bordetella pertussis toxin (Calbiochem, La Jolla, CA) were given i.p. 
Two weeks later arthritis was induced under inhalational isofluorane anaesthesia (Abbvie, 
Ludwigshafen, Germany) by intra-articular injection of 50 µg mBSA dissolved in 20 µl of PBS into 
the left knee joint cavity. Animals were analysed at sequential time points after arthritis induction 
reflecting different disease stages: acute arthritis (days 1-6), transition phase (day 10), early 
chronic (3-4 weeks) and late chronic arthritis (6-10 weeks).  
Histological analysis and scoring  
Knee joints were fixed in 4% buffered formaldehyde, decalcified with EDTA for 7-10 days, and 
embedded in paraffin. Serial sections (3–5 µm) were stained with HE for microscopic evaluation. 
Scoring of the knee sections was performed in a blinded manner with examination of four 
sections per joint. A multi-parameter scoring system was used (see Table 1) and individual 
scores were sumed up.  
Immunohistochemical analysis 
Paraffin sections were deparaffinised, pretreated with 5% donkey serum, followed by an anti-
RANKL antibody (polyclonal goat anti-mouse IgG, R&D Systems, Minneapolis), and a 
biotinylated donkey anti-goat antibody and streptavidin-conjugated horseradish peroxidase (SA-
HRP) (both JacksonImmunoResearch, Newmarket, UK). As isotype control we used goat serum 
as primary antibody. Enzyme reactions were developed with the AEC + Substrate Kit (DAKO, 
Hamburg, Germany). RANKL expression was quantified using ImageJ (1.48v) software, by 
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measuring the % of the area of the cartilage stained positive for RANKL. 
Spinal cord sections of the lumbar region innervating the knee joint (comprising nerve roots L4 
and L5)  were embedded in TissueTek O.C.T. (Sakura Finetek, Zoeterwoude, The Netherlands), 
snap frozen and cut using a microtome, dried and dehydrated with ice-cold acetone. For 
immunohistochemistry, cryosections were rehydrated in Tris buffer and stained with a rabbit anti-
substance P antibody (Zymed/Invitrogen, CA), followed by a biotinylated donkey anti-rabbit 
antibody (JacksonImmunoResearch) and SA-HRP. As isotype control we used rabbit serum. 
Enzyme reactions were developed as described above. 
Detection of antigen-specific immunoglobulins 
Anti-MVIIA antibodies were measured by flow cytometry. HEK293 cells transfected with a GFP-
MVIIA construct were incubated with serum from wt or Tg-MVIIA mice. MVIIA-specific antibodies 
were detected by a PE-labelled anti-mouse IgG detection antibody and the mean fluorescence 
intensity (MFI) was compared. mBSA-specific IgG titres in serum were determined by capture 
ELISA. Immunosorp microtiter plates (Nunc, Langenselbold, Germany) were coated with mBSA 
(Sigma-Aldrich). IgG and IgM capture and detection antibodies and standards were purchased 
from Southern Biotech (Eeling, Germany). For detection of ACPA Anti-MCV (Mutated 
Citrullinated Vimentin) plates were obtained from Orgentec Diagnostica (Mainz, Germany) and 
measurements were performed according to the manufacturer's protocol. Calf thymus DNA was 
purchased from Sigma-Aldrich. Bound antibodies were detected using peroxidase-conjugated 
rabbit anti-mouse antibodies (Southern Biotech) and TMB (tetramethylbenzidine) substrate 
solution (BD-Biosciences, Heidelberg, Germany) and analysed at 450 nm. 
Cytokine secretion assay 
The draining lymph nodes (popliteal and inguinal) were isolated at different disease stages and 
single cell suspensions were stimulated in vitro for 4h with phorbol 12-myristate 13-acetate 
(PMA)/ Ionomycin and Brefeldin A in RPMI supplemented with 10% heat-inactivated fetal calf 
serum, penicillin and streptomycin. Cells were stained for surface expression of CD4 (Biolegend) 
and intracellular expression of TNFα (Biolegend) and IL-17 (ebiosciences) using the Fix & Perm 
kit (Invitrogen, California, USA). Flow cytometry analyses were performed on a FACSCantoII (BD 
Biosciences). 
Motor activity, incapacitance test and intra-articular injections 
Motor activity was measured as distance covered in open field activity boxes (TSE Systems) for 
30 min. Pain was assessed in a blinded manner using an Incapacitance Meter (Harvard 
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Care; ACIA, Antigen- and Collagen-Induced Arthritis; ACPA, anti–citrullinated peptide antibodies; 
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To examine the contribution of CaV2.2 channels to the development of induced inflammatory 
arthritis we employed the genetic mouse model Tg(Scn10a-MVIIA-G109)Iit, hereafter 
abbreviated as Tg-MVIIA. This mouse expresses an isoform of the MVIIA conotoxin that is 
tethered to the cell-membrane and blocks the CaV2.2 channel (Fig. 1A,B) specifically in 
nociceptive neurons (9). Accurate expression of MVIIA in Tg-MVIIA mice was confirmed by RT-
PCR (Fig. 1C). Dorsal Root Ganglia (DRG), which contain the somata of nociceptive neurons, 
express MVIIA, Scn10a (BAC driver) and Cacna1b (alpha1B subunit of CaV2.2). MVIIA is also 
expressed in the knee of Tg-MVIIA mice at small but detectable amounts. Given that CaV2.2 is 
expressed not only in presynaptic terminals in the spinal cord, but also in the peripheral endings 
of nociceptors innervating the knee joint ((18) and Fig. 1C), we sought to test whether blocking of 
CaV2.2 channels in a cell-autonomous manner in nociceptors had an impact on knee joint 
inflammation in an autoimmune model of arthritis.  
Joint inflammation in Antigen-Collagen-induced Arthritis (ACIA) 
Knee joint inflammation was induced using our recently described model of combined Antigen-
and Collagen-Induced Arthritis (ACIA) (Fig. 2A). We evaluated the severity of inflammation and 
joint destruction by semiquantitative scoring of hematoxylin and eosin (HE) stained paraffin 
sections of the induced knee joint. As shown in Figure 2 and Table 1, this protocol induces a 
strong initial inflammation (acute arthritis) characterized by fibrin exudates and a severe 
neutrophil influx into the synovial cavity within the first days after arthritis induction (Fig. 2B). 
Subsequently, in the transition phase fibrin exudation ceases and mononuclear cells infiltrate the 
synovial cavity leading to synovial hyperplasia. Three weeks after arthritis induction, (early 
chronic phase), dense clusters of lymphocyte infiltrates are detected in the synovial and 
parasynovial tissue, as well as fibrosis and abrasion of cartilage and bone (Fig. 2C). Histological 
analysis revealed no differences between wt and Tg-MVIIA mice during the acute phase (Fig. 
2B). However, in the chronic phase Tg-MVIIA mice showed significantly higher scores for chronic 
inflammation (Fig. 2C, wt: CI 1.38-2.11; Tg-MVIIA: CI 3.79-4.87), and joint erosion with massive 
bone deformation (wt: CI 0.24–0.82; Tg-MVIIA: CI 1.9–3.07). 
Transgenic mice expressing MVIIA show no deficits in joint capacitance after arthritis 
induction. 
Since arthritis in humans often affects weight-bearing joints, we wanted to assess whether our 
ACIA joint inflammation model would evoke behavioural changes associated with pain, such as 
reduction in motor activity and differences in weight-bearing of the inflamed versus the non-
inflamed hind limb.  
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The motor activity of wt and Tg-MVIIA mice was tested in open field activity boxes at different 
days after arthritis induction by comparing the distance covered within 30 min. Both mouse 
groups travelled equal distances (Fig. 3A, F(3,61)=0.3415, p=0.79), indicating that inflammatory 
pain induced in by the ACIA model does not impair horizontal motor activity  
We performed a weight-bearing incapacitance test to assess whether the mice perceive pain 
from the induced inflammation on the left hind leg vs. the right, control leg. Mice were placed into 
a holder where the hind paws rest on two separate weight sensor plates. The postural 
equilibrium reflects a weight-bearing asymmetry, i.e. the level of discomfort in the arthritic knee 
joint. Before immunization (day 0) we observed no weight-bearing asymmetry in wt and Tg-
MVIIA mice as expected (Fig. 3B). During the acute (day 3) and transition (day 10) phases, wt 
mice bear significantly less weight on their inflamed leg (Fig. 3B, F(3,74)=6.028, p=0.001), while 
Tg-MVIIA show no weight-bearing asymmetry. This indicates that wt mice perveive pain that is 
maintained for the first 10 days after arthritis induction.  During the chronic arthritis phase (at day 
21), we observed no weight-bearing differences in wt mice indicating that pain or discomfort 
diminishes with time. This is in agreement with the histological findings in wt mice at this later 
stage (Fig. 2C), that shows that the joint inflammation resolves during the chronic phase. 
Remarkably, Tg-MVIIA mice showed no signs of weight-bearing asymmetry at any of the 
examined time points (Fig. 3B); they always bore the same weight on both, induced and non-
induced, hind limbs despite ongoing knee inflammation and joint deformation (Fig. 2C).  
Several possible mechanisms that may account for this enhanced induced-arthritis upon CaV2.2-
blockade could be proposed. Since CaV2.2 calcium influx triggers release of neurotransmitters 
and pro-inflammatory neuropeptides (i.e. substance P and calcitonin-gene related peptide 
(CGRP)), we analysed spinal cord sections at the level of the lumbar region innervating the knee 
for Substance P immunoreactivity. This analysis did not reveal apparent differences in the 
location or amount of substance P between both mouse groups (Fig. 3C). This finding indicates 
that CaV2.2 neurotransmission at the spinal level might not be the only component in pain 
transmission. Since MVIIA is also expressed in the knee (Fig.1C), we postulated that the 
analgesic effect of CaV2.2 blockade might take place locally in the joint. To test this hypothesis 
we injected soluble MVIIA in the inflamed knee of wt mice after induced arthritis. Interestingly 
mice no longer showed signs of pain, measured as weight-bearing deficits, both during the acute 
and transition phase (Fig. 3D, F(2,45)=21.93, p,0.0001). This finding indicates that local activity of 
CaV2.2 at peripheral nerve endings is critical for pain perception.  
Normal immune phenotype in Tg-MVIIA transgenic mice. 
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Tg-MVIIA mice develop a strikingly severe arthritis in the ACIA model in comparison to wt mice. 
Hence, we checked for a priori malprogramming in the immunological compartment of healthy 
untreated Tg-MVIIA mice. None of the lymphoid organs of Tg-MVIIA mice showed morphological 
abnormalities in size, structure or cellular aggregates and no differences were observed in their 
heart rate (Fig. 4A). The cellular compartment of the adaptive immune system, i.e. B and T cells, 
did not differ in total numbers or activation state between wt and Tg-MVIIA mice (Fig. 4B, 
F(3,40)=0.029, p=0.993). Since the presence of the MVIIA conotoxin at the cell-surface of 
nociceptors could have elicited an anti-MVIIA autoimmune response in these mice, we analysed 
serum from untreated Tg-MVIIA or wt mice for the presence of anti-MVIIA antibodies. However, 
MVIIA-specific antibodies were not detectable in the sera of Tg-MVIIA mice (Fig. 4C, 
autoantibodies: F(1,12)=0.025, p=0.87). In addition, Tg-MVIIA mice are not per se prone to 
autoimmunity. Basal levels of IgG as well as IgM autoantibodies directed to double-stranded 
DNA, which contribute to inflammation and tissue damage, do not differ between Tg-MVIIA and 
wt mice, and are significantly lower than those of autoimmune-prone mice such as RORγt–
deficient mice (19)(Fig. 4C IgM: F(2,16)=9.14, p=0.0022; IgG: F(2,16)=52.54, p<0.0001). 
Surprisingly, in contrast to the impressive difference in arthritis severity and joint deformation, the 
induction of ACPA (Anti-Citrullinated Peptide/Protein Antibodies), which are highly specific for RA, 
did not differ at any of the examined time points between wt or Tg-MVIIA mice (Fig. 4D, ACPA: 
F(4,64)=0.597, p=0.666), neither did the antibody response to the arthritis-inducing antigen mBSA 
(Fig. 4D; mBSA: F(4,63)=0.4054, p=0.8041).  
These results indicate that Tg-MVIIA mice have no gross defects in immunologic tolerance and 
that the observed differences in disease chronicity and joint destruction between wt and Tg-
MVIIA mice are indeed directly related to MVIIA blockade of CaV2.2 channels and reduced pain 
neurotransmission in these animals. 
 
Elevated TNFα and RANKL enhance inflammatory arthritis in pain-insensitive mice 
We wanted to evaluate whether inhibition of nociceptive neurotransmission interferes with the 
expression of inflammatory mediators that are involved in inflammation and bone destruction in 
order to shed some light on the underlying mechanisms that entail the severe destructive 
phenotype in Tg-MVIIA mice. 
Since TNFα is known to regulate the expression of RANKL, the main mediator of 
osteoclastogenesis and inflammatory bone resorption, we tested the ability of lymphocytes from 
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arthritic mice to produce TNFα upon restimulation. Cells from wt and Tg-MVIIA mice were 
isolated from the draining lymph nodes in different disease stages and stimulated in vitro with 
PMA and Ionomycin. Healthy untreated mice showed no difference in the ability of their CD4+ T 
cells to produce TNFα. However, during the acute phase, CD4+ T cells from Tg-MVIIA mice 
produced significantly more TNFα upon stimulation than cells from wt mice (Fig. 5A, p=0.006). 
Similarly, the levels of secreted IL-17 by T cells from Tg-MVIIA mice were significantly increased 
compared to wt in the transition phase (Fig. 5B, p=0.048). This suggests that increased 
proinflammatory cytokine production during the acute and transition phases of arthritis may 
contribute to the enhanced joint deformation in Tg-MVIIa mice. 
Given the evidence on the involvement of RANKL in arthritic bone damage, we sought to 
compare RANKL expression in the chronic stage of our ACIA model. Indeed, immunostaining for 
RANKL was more prominent in the knee joints of Tg-MVIIA mice compared to wt mice (Fig. 5C,D, 
p=0.026). Our study for the first time indicates that analgesic treatment by CaV2.2 blockade 
enhances RANKL expression and joint destruction.  
 
DISCUSSION  
The studies presented here establish that the CaV2.2 antagonist, conotoxin MVIIA 
(ziconotide/prialt), effectively blocks inflammatory pain in a mouse model of induced arthritis, but 
also reveal that this blockade severely enhances the ongoing joint inflammation and deformation. 
We show for the first time the deleterious impact of this type of analgesics on ongoing 
inflammation, suggesting that the activity of CaV2.2 channels in nociceptor neurons that innervate 
the injured joint is ultimately beneficial to re-establish the levels of proinflammatory cytokines and 
of the osteoclast-activator RANKL.  
In arthritis, as in other inflammatory disorders, pain intensity does not necessarily reflect disease 
activity, since pain often persists in patients with adequately controlled inflammation. Indeed, 
inflammation in the joint causes peripheral and central sensitization, which is thought to be the 
basis of arthritic pain that appears as spontaneous pain and hyperalgesia (20). Our finding adds 
to the growing evidence that the peripheral nervous and immune systems, traditionally thought to 
subserve separate functions, form an integrated protective mechanism. Nociceptors are not only 
highly sensitive to immune mediators, but can also release potent immune-acting mediators, 
actively modulating and coordinating immune responses (21) in pathological inflammations like 
colitis, psoriasis, asthma, and arthritis (22-25). It has therefore been suggested to target 
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nociceptors for the treatment of immune disorders (21). However, recent studies on interactions 
between immune cells and nociceptive neurons reveal contrarious effects. In certain 
immunopathologies denervation improves inflammation such as blockade of substance P in 
colitis and psoriasis, which dampens the damage mediated by T cells and other leukocytes (23, 
25). In contrast, mice lacking an acid-sensing channel present in nociceptors show signs of 
elevated inflammation during induced arthritis (26). In line with this study, our results point to 
devastating consequences of administering CaV2.2 inhibitors to patients suffering from arthritis 
even if these inhibitors provide pain relief. Our findings are reminiscent of the risks and benefits 
observed with antibodies against neurotrophin nerve-growth factor (NGF). NGF, similarly to 
CaV2.2, is a key regulator of peripheral nociception that mediates release of neurogenic 
molecules such as substance P and CGRP, and clinical studies using anti-NGF antibodies have 
shown a rapid and sustained pain reduction in patients (27), but long-term treatment has been 
reported to produce adverse effects in patients with advanced knee and hip osteoarthritis 
including peripheral edema, joint swelling and progressive osteoarthritis (28). Similarly, in a 
combined study analysis 21.3% of the ziconotide-treated patients reported abnormal gait as an 
adverse effect, compared to only 2% in the placebo group (29). This report also states that 9% of 
the ziconotide-group but none of the placebo-group developed arthralgia, i.e. joint pain. It is, at 
this point, unclear, if these effects are related to the intrathecal catheter or the actual compound.  
 
The aim of our study was to model the blockade of CaV2.2 specifically in nociceptors during 
arthritis, rather than to mimic the actual situation of intrathecal administration of ziconotide. This 
is relevant in view of the future use of more stable cyclic forms of peptide conotoxins that can be 
administered orally rather than intrathecally (8). In general, the present challenge in pain 
research is to identify orally active CaV2.2-inhibitors that block the channel in a voltage-
dependent manner (i.e. CRMP-2, NMED-160 and CNV2197944) to provide effective blocking 
only during high-frequency firing, which occurs in hypersensitive pain states (30). These novel 
use-dependent channel blockers, with oral availability, are now reported to be undergoing clinical 
evaluation for analgesia in neuropathic and inflammatory pain (30, 31). 
Given the role of TNFα and RANKL in osteoclastogenesis, bone loss and joint destruction in 
arthritis (15-17, 32) we investigated these molecules in our ACIA model with Tg-MVIIA mice. 
New biological therapies targeting TNFα, e.g. infliximab, adalimumab and etanercept have been 
successful in severe cases of rheumatoid arthritis (RA) where patients do not show an adequate 
response to conventional drugs (33). RANKL is regulated by inflammatory cytokines including 
 13 
TNFα, dictates the differentiation, activity and survival of osteoclasts  (34) and has been shown 
to be a marker and mediator of bone loss in rat models of inflammatory arthritis (32). 
Furthermore, postmenopausal osteoporosis and bone resorption have been reported to be 
successfully ameliorated by treatment with a monoclonal antibody to RANKL, denosumab (35). 
In our studies we observed for the first time that analgesic treatment, by CaV2.2 blockade with 
the conotoxin MVIIA, enhances RANKL-mediated joint destruction and progressive arthritis. This 
finding is intriguing. Additionally, after arthritis induction T cells from Tg-MVIIA mice were more 
prone to produce TNFα. Results from the intraarticular injection of soluble MVIIA point to a local, 
rather than central regulation of the pain blockade and we think that this is also the case for the 
regulation of RANKL and TNFα. We could not analyse the local, micromilieu (synovial fluid) for 
key molecules that are up- or down regulated in the absence of pain sensing, therefore we can 
only speculate on the mechanisms involved. Other studies suggest that CaV2.2 is involved in 
regulating monocyte chemotactic protein-1 (MCP-1), a cytokine that recruits monocytes, memory 
T cells, and dendritic cells to the sites of inflammation (36). In this context, CGRP has been 
shown to inhibit IL-1ß-induced endogenous MCP-1 secretion (37). These observations together 
with our findings point to the possibility that disruption of the local release of peptides by CaV2.2 
blockade might trigger an upregulation of RANKL, eventually leading to severe bone damage.  
There is clear evidence that the local release of proinflammatory neuropeptides from peripheral 
terminals of afferent nerve fibers contributes to the development of neurogenic inflammation. 
However, several studies report tissue-dependent differences regarding the mechanisms 
engaged by neuropeptides to initiate and maintain the inflammatory response in the target tissue 
(36, 38). Upregulation of substance P and CGRP has been observed in joints after adjuvant-
induced arthritis (39). In contrast, a reduction in the substance P-containing fibres in the 
synovium has also been reported (40), particularly in joints with heavy inflammatory infiltration, 
suggesting that the articular expression of nociceptive neuropeptides may be regulated 
differently at different stages of arthritis (41). It is possible that the basal activity of CaV2.2 is 
necessary for the proper homeostasis of the system. For instance, it has been speculated that 
inhibition of Ca2+ currents at sensory nerve endings may directly influence their sensitivity by 
changing the spike frequency adaptation (42, 43). It is also possible that other signalling events 
may take place upon reduction of CaV2.2 calcium influx.  
In conclusion, blocking CaV2.2 -mediated pain neurotransmission in our arthritis model amplified 
inflammatory events to such an extent that RANKL expression was enhanced, thus promoting 
osteoclast differentiation and activation and concomitant bone erosion and deformation. Despite 
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their obvious efficacy, the use of MVIIA peptide toxins and derivatives to alleviate pain in patients 
with inflammatory arthritis could be very harmful and ought to be assessed with extreme care. 
Further insight into the role of CaV2.2 channel activity and hyperactivity in the regulation of the 
complex crosstalk between the immune system and the nociceptive pathways might provide 
safer analgesic alternatives for the treatment of this most common cause of disability. 
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Figure legends: 
Figure 1. Mouse model for transgenic expression of the conotoxin MVIIA in nociceptors. (A) 
Scheme illustrating the sites of expression of the tethered conotoxin along the pain circuit. A 
nociceptor (red) with its soma in the dorsal root ganglion (DRG) projects bidirectionally to the 
spinal cord (blue circle) and to nerve endings in the knee joint (green circle). Tethered t-MVIIA (in 
purple) binds to CaV2.2 and blocks Ca2+ influx. (B) The BAC of the nociceptor specific Scn10a 
gene contains the tethered toxin expression cassette : MVIIA neurotoxin (red), flag epitope (light 
blue), linker (orange) and GPI anchor (green) that targets the molecule to the cell membrane, 
and restricts its action to receptors that are coexpressed on the cell surface. (C) RT-PCR 
analyses show MVIIA expression in DRG neurons and at lower levels in the knee of Tg-MVIIA 
mice and no expression in wt mice. Scn10a (used as BAC driver) is only detected in DRG cell 
bodies but not in the mouse knee. Cacna1b (encoding the α1B subunit of CaV2.2) was highly 
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expressed in DRG neurons, and at lower levels in knee joint preparations of wt and Tg-MVIIA 
mice at comparable levels. Actb: actin b used as control.  
Figure 2. Aggravated development of induced-arthritis in Tg-MVIIA mice. (A) Experimental 
timeline for the Antigen- and Collagen-induced arthritis (ACIA) model followed to induce RA in 
mice. mBSA: methylated bovine serum albumin, CFA: Complete Freunds’ Adjuvant, CII: bovine 
Collagen type II. (B,C) Histological assessment of knee joints by hematoxylin and eosin (H&E) 
staining in the acute (B) and chronic (C) phase of inflammation Arrows indicate cellular infiltrates 
and fibrinous exudates (in B), and cellular aggregates and synovial hyperplasia (in C). A multi-
parameter grading system was used (see Table I), where observation of the indicated individual 
signs of acute inflammation, chronic inflammation and joint destruction was assigned the 
indicated score (ranging form 1-3 for each parameter) and scores were summed up. The 
corresponding scores for wt and Tg-MVIIa mice are indicated in the graph. Statistics: Mann-
Whitney-Test, *** p < 0,001, n = 6-16 mice per group. Scale bars: 400 µm. 
Figure 3. Pain behaviour after arthritis induction. (A) Motor activity measured in open field 
activity boxes indicate no differences after arthritis induction, n = 5-9 mice per group. (B) Pain 
assessed with an Incapacitance Meter for weight-bearing measurements. Squares (wt) or circles 
(Tg-MVIIA) indicate the weight difference (in g) applied with the inflamed hindlimb minus the non-
treated hindlimb. During the acute and transition phases (days 3 and 10) wt mice (black line) 
bore significantly less weight on their inflamed hindlimb. Tg-MVIIA mice (dashed line) bore the 
same weight. ** p < 0,01; n = 5-9. (C) Similar Substance P immunoreactivity (red) during acute 
arthritis in wt and Tg-MVIIA spinal cord regions that innervate the knee joint. Bar 100 µm. (D) 
Intra-articular injection of soluble MVIIA abrogates pain sensing.in wt mice (red line) similarly to 
Tg-MVIIA mice (dashed line). Soluble MVIIA was injected into the inflamed knee joint and PBS in 
the contralateral joint every other day starting day 1 after arthritis induction and incapacitance 
was measured at day 3 and 10. Statistical differences are indicated by * between wt and Tg-
MVIIA, and by # between wt and wt injected with MVIIA. n = 5-12, bars show the mean and SEM. 
Figure 4. Analyses of autoimmune reactivity in Tg-MVIIA mice. (A) heart rates (bmp: beats per 
minute) of wt and Tg-MVIIA mice were comparable, n = 5-6. (B) Healthy wt or Tg-MVIIA mice 
have similar number of CD4+ T cells in the peripheral blood (naive: CD62Lhigh CD44low, effector: 
CD62Llow CD44high, memory: CD62Lhigh CD44high); n = 4-6.  (C, left) Test for autoantibody 
formation against t-MVIIA toxin in Tg-MVIIA mice. t-MVIIA transfected HEK-293 cells were 
incubated with serum from wt or Tg-MVIIA mice followed by a PE-labeled anti-mouse IgG 
detection antibody. Comparison of the mean fluorescence intensity (MFI) for wt and Tg-MVIIA 
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sera did not reveal the presence of MVIIA-specific autoantibodies in Tg-MVIIa mice; n = 4. (C, 
right) Test for anti double-stranded (ds) DNA antibodies as indicators of autoimmunity. Sera 
from wt and Tg-MVIIA mice were tested for IgM or IgG antibodies recognizing calf-thymus DNA. 
The levels of anti dsDNA antibodies were similar in wt and Tg-MVIIA and significantly lower than 
in the autoimmune-prone RORγt-deficient mice (positive control). n = 6. (D) Development of 
antibodies against mutated citrullinated vimentin (MCV/ACPA) and the arthritis-inducing antigen 
mBSA in wt and Tg-MVIIA mice. Sera of wt and Tg-MVIIA mice were analysed at consecutive 
indicated days after arthritis induction; n = 6-10. 
Figure 5. Tg-MVIIA mice express elevated levels of proinflammatory cytokines and of the 
osteoclast activator RANKL after induced arthritis. (A,B) Cytokine production by CD4+ T cells 
from lymph nodes draining the knee joint. Single cell suspensions from lymph nodes of wt and 
Tg-MVIIA mice at different stages of the disease were stimulated with PMA/Ionomycin and 
subsequently stained for expression of CD4, TNFα, and IL-17. (A) During the acute inflammation 
phase CD4+ T cells from Tg-MVIIA mice produced significantly more TNFα upon stimulation than 
CD4+ T cells from wt mice, (B) IL-17 levels were significantly increased in Tg-MVIIA compared to 
wt mice during the transition phase; n= 5-10 mice per group. (C,D) Enhanced expression of 
RANKL in arthritic joints of Tg-MVIIA mice. In the chronic phase of the disease, RANKL 
expression (in red, indicated by black arrows) is far more pronounced in the knee joints of Tg-
MVIIA mice than in joints of arthritic wt mice. Scale bars: 500 µm. (D) Quantification of RANKL 
immunoreactivity. Data is representative for 3 experiments. 
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Table 1.  Histological scoring of knee joint sections 
  
 
 
 
 
Parameter  
 
Score 1 
 
 
Score 2 
 
Score 3 
 
 
Acute 
inflammation  
 
granulocyte exudate scattered single 
cells 
patches of 
granulocytes 
massive 
exudate 
infiltration of synovial 
membrane with granulocytes 
single 
granulocytes 
small 
infiltrate 
dense 
infiltrates 
fibrin exudate exudate present - - 
 
 
 
Chronic 
inflammation  
 
synovial hyperplasia light hyperplasia moderate 
hyperplasia 
massive 
hyperplasia 
infiltration of synovial 
membrane by mononuclear cells 
light moderate dense 
infiltrates 
 
periarticular structures 
light fibrosis and 
small cellular 
infiltrates 
moderate 
fibrosis and 
infiltrates 
massive 
fibrosis and 
dense 
infiltrates 
 
 
Destruction  
 
destruction and deformation of 
articular surface 
minimal > 10% > 50% 
pannus small pannus several 
patches 
excessive 
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Figure 1. Mouse model for transgenic expression of the conotoxin MVIIA in nociceptors. (A) Scheme 
illustrating the sites of expression of the tethered conotoxin along the pain circuit. A nociceptor (red) with its 
soma in the dorsal root ganglion (DRG) projects bidirectionally to the spinal cord (blue circle) and to nerve 
endings in the knee joint (green circle). Tethered t-MVIIA (in purple) binds to CaV2.2 and blocks Ca2+ 
influx. (B) The BAC of the nociceptor specific Scn10a gene contains the tethered toxin expression cassette : 
MVIIA neurotoxin (red), flag epitope (light blue), linker (orange) and GPI anchor (green) that targets the 
molecule to the cell membrane, and restricts its action to receptors that are coexpressed on the cell surface. 
(C) RT-PCR analyses show MVIIA expression in DRG neurons and at lower levels in the knee of Tg-MVIIA 
mice and no expression in wt mice. Scn10a (used as BAC driver) is only detected in DRG cell bodies but not 
in the mouse knee. Cacna1b (encoding the α1B subunit of CaV2.2) was highly expressed in DRG neurons, 
and at lower levels in knee joint preparations of wt and Tg-MVIIA mice at comparable levels. Actb: actin b 
used as control.  
192x82mm (300 x 300 DPI)  
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Figure 2. Aggravated development of induced-arthritis in Tg-MVIIA mice. (A) Experimental timeline for the 
Antigen- and Collagen-induced arthritis (ACIA) model followed to induce RA in mice. mBSA: methylated 
bovine serum albumin, CFA: Complete Freunds’ Adjuvant, CII: bovine Collagen type II. (B,C) Histological 
assessment of knee joints by hematoxylin and eosin (H&E) staining in the acute (B) and chronic (C) phase 
of inflammation Arrows indicate cellular infiltrates and fibrinous exudates (in B), and cellular aggregates and 
synovial hyperplasia (in C). A multi-parameter grading system was used (see Table I), where observation of 
the indicated individual signs of acute inflammation, chronic inflammation and joint destruction was assigned 
the indicated score (ranging form 1-3 for each parameter) and scores were summed up. The corresponding 
scores for wt and Tg-MVIIa mice are indicated in the graph. Statistics: Mann-Whitney-Test, *** p < 0,001, 
n = 6-16 mice per group. Scale bars: 400 µm.  
218x299mm (300 x 300 DPI)  
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Figure 3. Pain behaviour after arthritis induction. (A) Motor activity measured in open field activity boxes 
indicate no differences after arthritis induction, n = 5-9 mice per group. (B) Pain assessed with an 
Incapacitance Meter for weight-bearing measurements. Squares (wt) or circles (Tg-MVIIA mice) indicate the 
weight difference (in g) applied with the inflamed hindlimb minus the non-treated hindlimb. During the acute 
and transition phases (days 3 and 10) wt mice (black line) bore significantly less weight on their inflamed 
hindlimb. Tg-MVIIA mice (dashed line) bore the same weight. ** p < 0,01; n = 5-9. (C) Similar Substance P 
immunoreactivity (red) during acute arthritis in wt and Tg-MVIIA spinal cord regions that innervate the knee 
joint. Bar 100 µm. (D) Soluble MVIIA abrogates pain sensing. Tg-MVIIA mice (dashed line) and wt mice 
after intraarticular injection of soluble MVIIA into the inflamed knee joint from day 1 after arthritis (red line) 
show no weight-bearing asymmetry in the incapacitance test. Statistical differences are indicated by * 
between wt and Tg-MVIIA, and by # between wt and wt injected with MVIIA. n = 5-12, bars show the mean 
and SEM.  
225x164mm (300 x 300 DPI)  
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Figure 4. Analyses of autoimmune reactivity in Tg-MVIIA mice. (A) heart rates (bmp: beats per minute) of 
wt and Tg-MVIIA mice were comparable, n = 5-6. (B) Healthy wt or Tg-MVIIA mice have similar number of 
CD4+ T cells in the peripheral blood (naive: CD62Lhigh CD44low, effector: CD62Llow CD44high, memory: 
CD62Lhigh CD44high); n = 4-6.  (C, left) Test for autoantibody formation against t-MVIIA toxin in Tg-MVIIA 
mice. t-MVIIA transfected HEK-293 cells were incubated with serum from wt or Tg-MVIIA mice followed by a 
PE-labeled anti-mouse IgG detection antibody. Comparison of the mean fluorescence intensity (MFI) for wt 
and Tg-MVIIA sera did not reveal the presence of MVIIA-specific autoantibodies in Tg-MVIIa mice; n = 4. (C, 
right) Test for anti double-stranded (ds) DNA antibodies as indicators of autoimmunity. Sera from wt and 
Tg-MVIIA mice were tested for IgM or IgG antibodies recognizing calf-thymus DNA. The levels of anti dsDNA 
antibodies were similar in wt and Tg-MVIIA and significantly lower than in the autoimmune-prone RORγt-
deficient mice (positive control). n = 6. (D) Development of antibodies against mutated citrullinated 
vimentin (MCV/ACPA) and the arthritis-inducing antigen mBSA in wt and Tg-MVIIA mice. Sera of wt and Tg-
MVIIA mice were analysed at consecutive indicated days after arthritis induction; n = 6-10.  
186x135mm (300 x 300 DPI)  
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Figure 5. Tg-MVIIA mice express elevated levels of proinflammatory cytokines and of the osteoclast 
activator RANKL after induced arthritis. (A,B) Cytokine production by CD4+ T cells from lymph nodes 
draining the knee joint. Single cell suspensions from lymph nodes of wt and Tg-MVIIA mice at different 
stages of the disease were stimulated with PMA/Ionomycin and subsequently stained for expression of CD4, 
TNFα, and IL-17. (A) During the acute inflammation phase CD4+ T cells from Tg-MVIIA mice produced 
significantly more TNFα upon stimulation than CD4+ T cells from wt mice, (B) IL-17 levels were significantly 
increased in Tg-MVIIA compared to wt mice during the transition phase; n= 5-10 mice per group. (C,D) 
Enhanced expression of RANKL in arthritic joints of Tg-MVIIA mice. In the chronic phase of the disease, 
RANKL expression (in red, indicated by black arrows) is far more pronounced in the knee joints of Tg-MVIIA 
mice than in joints of arthritic wt mice. Scale bars: 500 µm. (D) Quantification of RANKL immunoreactivity. 
Data is representative for 3 experiments.  
191x143mm (300 x 300 DPI)  
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Parameter  
 
Score 1 
 
 
Score 2 
 
Score 3 
 
 
Acute 
inflammation  
 
granulocyte exudate scattered single 
cells 
patches of 
granulocytes 
massive 
exudate 
infiltration of synovial 
membrane with granulocytes 
single 
granulocytes 
small 
infiltrate 
dense 
infiltrates 
fibrin exudate exudate present - - 
 
 
 
Chronic 
inflammation  
 
synovial hyperplasia light hyperplasia moderate 
hyperplasia 
massive 
hyperplasia 
infiltration of synovial 
membrane by mononuclear cells 
light moderate dense 
infiltrates 
 
periarticular structures 
light fibrosis and 
small cellular 
infiltrates 
moderate 
fibrosis and 
infiltrates 
massive 
fibrosis and 
dense 
infiltrates 
 
 
Destruction  
 
destruction and deformation of 
articular surface 
minimal > 10% > 50% 
pannus small pannus several 
patches 
excessive 
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